Biosimulation refers to the simulation of biological processes using a computer program. It is used as a tool used in the discovery stage to determine the future outcomes of current experimental trials. It is also used for model-based calculation of biological systems and processes and aided by a computer. The global biosimulation market is projected to reach $3.12 Billion by 2024 from $1.38 Billion in 2017, at a CAGR of 15.9%. Growing adoption of biosimulation software by regulatory bodies and increase in R&D investments in the pharmaceutical and biotechnology industries are the drivers boosting the market growth. On the flip side, lack of standardisation and shortage of biosimulation and modelling experts are the factors hampering the market growth. Increased use of personalised medicine and use of biosimulation solution for paediatric drug development are the opportunities driving the market.
Research Study Objectives:
Top-down and bottom-up approaches are used to validate the Biosimulation Market Size and are used to estimate the size of other dependent submarkets. Key players in the
Starting from $2700
Starting from $2700
Starting from $2700
Keep up-to-date with our weekly newsletter, Media Pulse.